Ex vivo induction and expansion of natural killer T cells by CD1d1-Ig coated artificial antigen presenting cells

Journal of Immunological Methods

Volumn 346, Issue 1-2, 2009, Pages 38-44

  Webb, Tonya J ^a   Bieler, Joan G ^a   Schneck, Jonathan P ^a   Oelke, Mathias ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

aAPC; CD1d; NKT cells

Indexed keywords

CD1D ANTIGEN; IMMUNOGLOBULIN;

ADOPTIVE IMMUNOTHERAPY; ANIMAL CELL; ANTIGEN PRESENTATION; ANTIGEN PRESENTING CELL; ARTICLE; CANCER PATIENT; CD3+ T LYMPHOCYTE; CELL EXPANSION; CONTROLLED STUDY; EFFECTOR CELL; EX VIVO STUDY; HUMAN; HUMAN CELL; LYMPHOCYTOPOIESIS; MATERIAL COATING; MOUSE; NATURAL KILLER T CELL; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL;

ANIMALS; ANTIGEN-PRESENTING CELLS; ANTIGENS, CD1D; ANTIGENS, CD3; CASE-CONTROL STUDIES; CELL PROLIFERATION; CERAMIDES; CYTOKINES; HUMANS; HYBRIDOMAS; IMMUNOGLOBULINS; IMMUNOTHERAPY, ADOPTIVE; LYMPHOCYTE ACTIVATION; MICE; MICE, INBRED C57BL; NATURAL KILLER T-CELLS; NEOPLASMS; NK CELL LECTIN-LIKE RECEPTOR SUBFAMILY B; RECEPTORS, ANTIGEN, T-CELL; TIME FACTORS;

EID: 67449146881     PISSN: 00221759     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jim.2009.05.003     Document Type: Article

References (30)

1. Bella, S.D., Gennaro, M., Vaccari, M., Ferraris, C., Nicola, S., Riva, A., Clerici, M., Greco, M., Villa, M.L., 2003. Altered maturation of peripheral blood dendritic cells in patients with breast cancer. Br. J. Cancer 89, 1463.
2. + T lymphocytes. Science 268 (1995) 863
3. 2-microglobulin-dependent surface expression of functional mouse CD1.1. J. Exp. Med. 182 (1995) 1913
4. + NK T lymphocytes. J. Immunol. 161 (1998) 3271
5. Chang D.H., Osman K., Connolly J., Kukreja A., Krasovsky J., Pack M., Hutchinson A., Geller M., Liu N., Annable R., Shay J., Kirchhoff K., Nishi N., Ando Y., Hayashi K., Hassoun H., Steinman R.M., and Dhodapkar M.V. Sustained expansion of NKT cells and antigen-specific T cells after injection of alpha-galactosyl-ceramide loaded mature dendritic cells in cancer patients. J. Exp. Med. 201 (2005) 1503
6. Croudace J.E., Curbishley S.M., Mura M., Willcox C.R., Illarionov P.A., Besra G.S., Adams D.H., and Lammas D.A. Identification of distinct human invariant natural killer T-cell response phenotypes to alpha-galactosylceramide. BMC Immunol. 9 (2008) 71
7. Durai M., Krueger C., Ye Z., Cheng L., Mackensen A., Oelke M., and Schneck J.P. In vivo functional efficacy of tumor-specific T cells expanded using HLA-Ig based artificial antigen presenting cells (aAPC). Cancer Immunol. Immunother. 58 (2009) 209
8. Fujii S., Shimizu K., Klimek V., Geller M.D., Nimer S.D., and Dhodapkar M.V. Severe and selective deficiency of interferon-gamma-producing invariant natural killer T cells in patients with myelodysplastic syndromes. Br. J. Haematol. 122 (2003) 617
9. Giaccone G., Punt C.J., Ando Y., Ruijter R., Nishi N., Peters M., Von Blomberg B.M., Scheper R.J., Van Der Vliet H.J., Van Den Eertwegh A.J., Roelvink M., Beijnen J., Zwierzina H., and Pinedo H.M. A phase I study of the natural killer T-cell ligand α-galactosylceramide (KRN7000) in patients with solid tumors. Clin. Cancer Res. 8 (2002) 3702
10. Harada Y., Imataki O., Heike Y., Kawai H., Shimosaka A., Mori S., Kami M., Tanosaki R., Ikarashi Y., Iizuka A., Yoshida M., Wakasugi H., Saito S., Takaue Y., Takei M., and Kakizoe T. Expansion of alpha-galactosylceramide-stimulated Valpha24+ NKT cells cultured in the absence of animal materials. J. Immunother. 28 (2005) 314
11. Huang M.M.S., Borszcz P., Sidobre S., Kronenberg M., and Kane K.P. CD1d1 displayed on cell size beads identifies and enriches an NK cell population negatively regulated by CD1d1. J. Immunol. 172 (2004) 5304
12. Imataki O., Heike Y., Makiyama H., Iizuka A., Ikarashi Y., Ishida T., Wakasugi H., and Takaue Y. Insufficient ex vivo expansion of Valpha24(+) natural killer T cells in malignant lymphoma patients related to the suppressed expression of CD1d molecules on CD14(+) cells. Cytotherapy (2008) 1
13. Kawano T., Nakayama T., Kamada N., Kaneko Y., Harada M., Ogura N., Akutsu Y., Motohashi S., Iizasa T., Endo H., Fujisawa T., Shinkai H., and Taniguchi M. Antitumor cytotoxicity mediated by ligand-activated human Vα24 NKT cells. Cancer Res. 59 (1999) 5102
14. - T cells in mice and humans. J. Exp. Med. 180 (1994) 1097
15. Larkin J., Renukaradhya G.J., Sriram V., Du W., Gervay-Hague J., and Brutkiewicz R.R. CD44 differentially activates mouse NK T cells and conventional T cells. J. Immunol. 177 (2006) 268
16. H2 bias of natural killer T cells. Nature 413 (2001) 531
17. Molling J.W., Kolgen W., van der Vliet H.J., Boomsma M.F., Kruizenga H., Smorenburg C.H., Molenkamp B.G., Langendijk J.A., Leemans C.R., von Blomberg B.M., Scheper R.J., and van den Eertwegh A.J. Peripheral blood IFN-gamma-secreting Valpha24+Vbeta11+ NKT cell numbers are decreased in cancer patients independent of tumor type or tumor load. Int. J. Cancer 116 (2005) 87
18. Naidenko O.V., Maher J.K., Ernst W.A., Sakai T., Modlin R.L., and Kronenberg M. Binding and antigen presentation of ceramide-containing glycolipids by soluble mouse and human CD1d molecules. J Exp Med 190 (1999) 1069
19. Nieda M., Okai M., Tazbirkova A., Lin H., Yamaura A., Ide K., Abraham R., Juji T., Macfarlane D.J., and Nicol A.J. Therapeutic activation of Valpha24+Vbeta11+ NKT cells in human subjects results in highly coordinated secondary activation of acquired and innate immunity. Blood 103 (2004) 383
20. Oelke M., Maus M.V., Didiano D., June C.H., Mackensen A., and Schneck J.P. Ex vivo induction and expansion of antigen-specific cytotoxic T cells by HLA-Ig-coated artificial antigen-presenting cells. Nat. Med. 9 (2003) 619
21. Onishi H., Morisaki T., Baba E., Kuga H., Kuroki H., Matsumoto K., Tanaka M., and Katano M. Dysfunctional and short-lived subsets in monocyte-derived dendritic cells from patients with advanced cancer. Clin. Immunol. 105 (2002) 286
22. Park J.-E., Wu D.Y., Prendes M., Lu S.X., Ragupathi G., Schrantz N., and Chapman P.B. Fine specificity of natural killer T cells against GD3 ganglioside and identification of GM3 as an inhibitory natural killer T-cell ligand. Immunology 123 (2008) 145
23. Roberts T.J., Sriram V., Spence P.M., Gui M., Hayakawa K., Bacik I., Bennink J.R., Yewdell J.W., and Brutkiewicz R.R. Recycling CD1d1 molecules present endogenous antigens processed in an endocytic compartment to NKT cells. J. Immunol. 168 (2002) 5409
24. Schumann J., Voyle R.B., Wei B.-Y., and MacDonald H.R. Cutting edge: influence of the TCR V{beta} domain on the avidity of CD1d:{alpha}-galactosylceramide binding by invariant V{alpha}14 NKT cells. J. Immunol. 170 (2003) 5815
25. Schutz C., Fleck M., Mackensen A., Zoso A., Halbritter D., Schneck J.P., and Oelke M. Killer artificial antigen-presenting cells: a novel strategy to delete specific T cells. Blood 111 (2008) 3546
26. Shimizu K., Hidaka M., Kadowaki N., Makita N., Konishi N., Fujimoto K., Uchiyama T., Kawano F., Taniguchi M., and Fujii S. Evaluation of the function of human invariant NKT cells from cancer patients using alpha-galactosylceramide-loaded murine dendritic cells. J. Immunol. 177 (2006) 3484
27. Sriram V., Du W., Gervay-Hague J., and Brutkiewicz R.R. Cell wall glycosphingolipids of Sphingomonas paucimobilis are CD1d-specific ligands for NKT cells. Eur. J. Immunol. 35 (2005) 1692
28. Tahir S.M., Cheng O., Shaulov A., Koezuka Y., Bubley G.J., Wilson S.B., Balk S.P., and Exley M.A. Loss of IFN-gamma production by invariant NK T cells in advanced cancer. J. Immunol. 167 (2001) 4046
29. Tupin E., and Kronenberg M. Activation of natural killer T cells by glycolipids. Methods Enzymol. 417 (2006) 185
30. Vasan S., Poles M.A., Horowitz A., Siladji E.E., Markowitz M., and Tsuji M. Function of NKT cells, potential anti-HIV effector cells, are improved by beginning HAART during acute HIV-1 infection. Int. Immunol. 19 (2007) 943